Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
Gilead to Acquire Forty Seven for $4.9 Billion
FOSTER CITY, Calif. & MENLO PARK, Calif., March 2, 2020 - Gilead Sciences, Inc. (Nasdaq: GILD) and Forty Seven, Inc. (Nasdaq: FTSV) announced today th…
Kymera Therapeutics Announces $102 Million Series C Financing
Cambridge, Mass (March 12, 2020) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough pr…
Ryvu Therapeutics receives Orphan Drug Designation from FDA
Krakow, Poland – 28 March 2020 – Ryvu Therapeutics (WSE: RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies th…
Affimed Announces FDA Granted Orphan Drug Designation
Heidelberg, Germany, April 1, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their inn…
Stemline Therapeutics to be Acquired by Menarini Group
FLORENCE, Italy and NEW YORK, May 04, 2020 - Menarini Group, a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutic…
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
